Study finds that patients with glioblastoma who received gabapentin lived longer

A new study by investigators from Mass General Brigham suggests that gabapentin, a relatively common anti-seizure/pain medication, is linked to improved survival in patients with glioblastoma (GBM)—the most common and deadly form of brain cancer in adults. The findings, published in Nature Communications, are based on a retrospective analysis and add new evidence to help patients with this devastating disease.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup